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Ischemia-reperfusion (IR) injury occurs when blood supply to an organ is disrupted - 
ischemia – and then restored – reperfusion, leading to a burst of reactive oxygen species 
(ROS) from mitochondria. It has been tacitly assumed that ROS production during IR is a 
non-specific consequence of oxygen interacting with dysfunctional mitochondria upon 
reperfusion. Recently, this view has changed suggesting that ROS production during IR 
occurs by a defined mechanism. Here we survey the metabolic factors underlying IR 
injury, and propose a unifying mechanism for its causes that makes sense of the huge 
amount of disparate data in this area and provides testable hypotheses and new directions 
for therapies.  
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Introduction 
Ischemia-reperfusion (IR) injury occurs when the blood supply to a tissue is blocked for 
minutes to hours (ischemia), and then restored (reperfusion) (Eltzschig and Eckle, 2011; 
Hausenloy and Yellon, 2013). This pervasive pathological mechanism underlies a range 
of disorders, including heart attack and stroke, where the prevention of blood flow to the 
tissue, for example by a blood clot, is followed by reperfusion when the blockage is 
removed mechanically or pharmacologically (Pan et al., 2007; Yellon and Hausenloy, 
2007). Similar situations affect many other tissues, for example during organ 
transplantation (Jaeschke and Woolbright, 2012), elective surgery (Hausenloy et al., 
2012) or hypovolemic shock (Gutierrez et al., 2004). Consequently, there has been an 
enduring interest in understanding the nature of IR injury and in developing therapies to 
prevent or ameliorate its effects (Bernardi et al., 2015; Eltzschig and Eckle, 2011; 
Hausenloy and Yellon, 2013; Murphy and Steenbergen, 2008b; Yellon and Hausenloy, 
2007).  
The current consensus is that a period of ischemia primes the tissue for 
subsequent damage upon reperfusion, with the duration of ischemia required for 
reperfusion injury varying with tissue (Burwell et al., 2009; Jaeschke and Woolbright, 
2012; Murphy and Steenbergen, 2008b; Pan et al., 2007). Ischemic cells will eventually 
die if blood flow is not restored, but it is during reperfusion itself that most IR damage is 
initiated. Thus paradoxically, the essential therapeutic intervention to treat ischemia - 
reperfusion – drives tissue pathophysiology (Murphy and Steenbergen, 2008b). The first 
few minutes of reperfusion are critical, because what happens then initiates long-term 
tissue damage and dysfunction (Eltzschig and Eckle, 2011). Early studies suggested a 
role for mitochondrial activity early in IR injury (Ganote et al., 1976). The first damaging 
event upon reperfusion is a burst of reactive oxygen species (ROS) production from 
mitochondria (Loor et al., 2011; Zweier et al., 1987). Mitochondrial ROS not only drive 
acute damage but also initiate the pathology that develops over the minutes, days and 
weeks following reperfusion (Eltzschig and Eckle, 2011). The initial burst of ROS 
production upon reperfusion directly causes oxidative damage to mitochondria, thereby 
disrupting ATP production (Murphy and Steenbergen, 2008b). In conjunction with 
dysregulation of calcium levels, this elevated ROS can also lead to induction of the 
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mitochondrial permeability transition (Bernardi et al., 2015; Burwell et al., 2009; Di Lisa 
and Bernardi, 2015; Halestrap, 2010). Together, this mitochondrial disruption leads to 
necrotic and apoptotic cell death following reperfusion (Loor et al., 2011; Murphy and 
Steenbergen, 2008b). ROS-mediated mitochondrial damage will also release damage-
associated molecular pattern molecules (DAMPs), such as mitochondrial DNA, which 
can initiate the sterile inflammatory response (Arslan et al., 2011; Chen and Nunez, 2010; 
Kawaguchi et al., 2011). This activation of the innate immune system causes 
inflammation that contributes to IR injury and can continue for days after the initial 
damage (Arslan et al., 2011). Therefore, during the weeks and months following the 
initial IR injury there will be formation of fibrotic scar tissue to replace the dead cells 
along with extensive tissue remodeling (Frangogiannis, 2012). The end result is often an 
organ that is structurally altered and functions poorly, frequently leading to persistent 
long-term pathology such as chronic heart disease (White et al., 1987).  
The causes of mitochondrial ROS production upon reperfusion are still unclear; 
the tacit assumption has been that the underlying mechanisms are imprecise and 
complicated. This view is consistent with the bewildering range of interventions that 
decrease IR injury (Burwell et al., 2009; Kornfeld et al., 2015; Murphy et al., 2012; 
Murphy and Steenbergen, 2008a, b). However, recent findings suggest instead that there 
is a common pathway for the initial burst of mitochondrial ROS production that underlies 
IR injury. Here we present a model that can rationalize the vast array of data in this area. 
To do this we first survey the literature on mitochondrial ROS production during IR and 
then propose a unifying hypothesis for how reperfusion injury occurs. Better 
understanding of this process should make it possible to develop therapies that limit this 
early event in IR injury, and thereby blunt the subsequent pathological cascade.   
 
Mitochondrial superoxide formation upon reperfusion of ischemic tissue initiates 
ischemia-reperfusion (IR) injury 
There is consensus that a major damaging event upon reperfusion of ischemic tissue is a 
burst of ROS production. This was first proposed by Hess and Manson (Hess and 
Manson, 1984), demonstrated by Zweier and colleagues (Zweier et al., 1987), and 
confirmed by many others since (e.g. Murphy and Steenbergen, 2008b). This ROS 
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production arises as a burst of superoxide from mitochondria upon reperfusion, as has 
been corroborated in a range of tissues and types of IR injury (Burwell et al., 2009; Crack 
and Taylor, 2005; Jaeschke and Woolbright, 2012; Padanilam, 2003). Superoxide itself 
can cause damage, but also acts through the formation of hydrogen peroxide and other 
damaging reactive species (Murphy, 2009). There are a number of other sources of 
superoxide outside the mitochondrion that may also contribute to IR injury, for example 
xanthine oxidase (Linas et al., 1990) and NADPH oxidases (NOX) (Braunersreuther et 
al., 2013). However, activation of these processes seems to occur after the initial burst of 
mitochondrial ROS and their role in the proximal cascade of reperfusion pathology is 
unclear, suggesting that non-mitochondrial ROS contributes to secondary tissue damage 
and subsequent inflammation (Abramov et al., 2007). So, although these non-
mitochondrial ROS sources are important contributors to the progression of the pathology 
in the hours that follow reperfusion, the role of mitochondrial ROS upon initiation of 
reperfusion seems to be critical and is our focus.  
Initial work on mitochondrial ROS production during reperfusion used electron 
spin resonance in conjunction with spin traps to identify a flux of radical species in the 
first minutes of reperfusion (Arroyo et al., 1987; Bolli et al., 1989; Garlick et al., 1987; 
Zweier et al., 1987). More recently, fluorescence methods to detect reactive species in the 
outer layer of the heart (Pasdois et al., 2008), and mass spectrometric tools for the 
assessment of changes in mitochondrial hydrogen peroxide levels in vivo (Cocheme et al., 
2011), have further demonstrated mitochondrial ROS production in the first few minutes 
of myocardial reperfusion (Chouchani et al., 2013; Chouchani et al., 2014). While most 
work has been on IR injury in the heart, similar findings have been found in studies in 
many other organs, including the brain (Kontos et al., 1992; Nelson et al., 1992), liver 
(Mukhopadhyay et al., 2012), and kidney (Dare et al., 2015). Together these data provide 
a strong body of evidence that reperfusion of ischemic tissue drives a burst of superoxide 
production in mitochondria.  
Preventing the damage caused by this ROS production is a promising therapeutic 
strategy against IR injury, although many other therapeutic interventions can act later in 
the pathological cascade. Therefore, our working assumption is that the production of 
superoxide by mitochondria over the first few minutes of reperfusion is the essential 
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trigger in pathological IR injury. 
 
Is complex I the major source of mitochondrial superoxide during reperfusion?  
During ischemia the respiratory chain, redox active enzymes, and electron carrier pools 
such as NADH and CoenzymeQ (CoQ) become maximally reduced. In parallel, 
mitochondria become progressively compromised due to factors such as ATP depletion, 
lack of ion homeostasis, calcium overload, and changes in pH (Burwell et al., 2009). 
Consequently, when ischemic tissue is reperfused with oxygenated blood, the tacit 
assumption has been that inappropriately reduced and damaged mitochondrial 
components will spill electrons onto oxygen from numerous sites to form superoxide 
(Hausenloy and Yellon, 2013; Murphy and Steenbergen, 2008b). While this model of 
non-specific superoxide production at multiple sites within mitochondria has appeal, 
there is now a large amount of evidence that points to respiratory complex I as the major 
source of mitochondrial superoxide upon reperfusion. Complex I is the entry point for 
electrons from NADH into the mitochondrial respiratory chain (Figure 1A), and is well 
established as a major source of mitochondrial superoxide in vitro (Murphy, 2009). 
Direct evidence for complex I as the major source of superoxide upon reperfusion comes 
from the fact that its selective pharmacological inhibition protects from reperfusion injury 
and ROS production (Chen et al., 2006a, b; Lesnefsky et al., 2004; Niatsetskaya et al., 
2012). 
While this evidence is consistent with complex I being the main site of 
mitochondrial superoxide production upon reperfusion, it does not eliminate the 
possibility that other sites, such as complex III, also contribute. However, a major reason 
for supporting a dominant role for complex I in superoxide production during reperfusion 
is that the conditions that favor complex I superoxide production are present during IR 
injury, in contrast to other potential sites of superoxide. Therefore, we next consider how 
complex I can produce superoxide during IR injury.  
 
Reverse electron transport (RET) at complex I generates superoxide upon 
reperfusion 
 7 
Complex I produces superoxide under two conditions (Hinkle et al., 1967; Murphy, 2009; 
St-Pierre et al., 2002). The first occurs during conventional forward electron transport and 
arises when the flavin mononucleotide (FMN) that accepts electrons from NADH 
becomes reduced (Cadenas et al., 1977) (Figure 1A). This occurs, for example, when 
complex I is inhibited by the CoenzymeQ (CoQ)-site inhibitor rotenone, or when 
respiration rate is decreased by mitochondrial damage (Murphy, 2009; Pryde and Hirst, 
2011). However, complex I inhibitors such as rotenone decrease ROS and oxidative 
damage during IR, and protect against reperfusion injury (Chen et al., 2006a, b; 
Lesnefsky et al., 2004), indicating that superoxide production associated with forward 
electron transfer at complex I is unlikely to contribute to IR injury. The other mode of 
superoxide production by complex I is that associated with reverse electron transport 
(RET) (Adam-Vizi and Chinopoulos, 2006; Chance, 1961; Chance and Hollunger, 1961; 
Kudin et al., 2004). RET at complex I has been known since the 1960s (Chance, 1961; 
Chance and Hollunger, 1961), but has generally been assumed to be an in vitro curiosity 
of uncertain physiological significance (Murphy, 2009). However, as delineated below, 
RET at complex I seems likely to be the main source of superoxide upon reperfusion of 
ischemic tissue. 
RET occurs when electrons are forced backwards through complex I (Figure 1B), 
in contrast to conventional forward transport (Figure 1A). In forward operation two 
electrons transfer from NADH to reduce CoQ to CoQH2, and the redox energy difference 
drives the pumping of four protons across the mitochondrial inner membrane to maintain 
the protonmotive force (p) that drives ATP synthesis (Figure 1A). For forward operation 
the redox driving force (Eh) that pushes two electrons from NADH to CoQ has to be 
greater than the energy required to pump four protons across the inner membrane against 
the protonmotive force (p): 2Eh > 4p (Figure 1A). However, as the overall reaction is 
not displaced far from thermodynamic equilibrium the direction of electron transport can 
be reversed if the p is high and/or the CoQ pool is reduced so that 4p > 2Eh (Figure  
1B) (Murphy, 2009). If these conditions are met electrons flow backwards through 
complex I and onto the FMN from where they can reduce NAD+ to NADH and also drive 
superoxide formation (Murphy, 2009). 
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Both the FMN and the CoQ reduction sites of complex I have been proposed as 
sites of superoxide production from complex I during RET (Lambert et al., 2008; Pryde 
and Hirst, 2011). We favor the FMN site, because from current complex I structures it is 
difficult to see how oxygen could access the CoQ site and there generate a negatively-
charged superoxide molecule that could migrate in the low dielectric of the bilayer and 
also diffuse against the membrane potential to the matrix (Vinothkumar et al., 2014; 
Zickermann et al., 2015). An important additional point is that superoxide production 
during RET still occurs even when there is no reduction of NAD+ to NADH. Numerous 
experiments have shown extensive superoxide production from complex I with no net 
reduction of NAD+ in the presence of a highly reduced NAD+/NADH pool (e.g Hirst et 
al., 2008). Superoxide production occurs during RET, despite no net NAD+ reduction, 
because as electrons build up on FMN they can then either reduce NAD+ or drive 
reduction of oxygen to superoxide (Pryde and Hirst, 2011) (Figure 1B). This mechanism 
enables complex I to continue to produce superoxide when the FMN site is at equilibrium 
with the NADH and CoQ pools, and the p (Figure 1B). Consequently under most 
conditions when RET drives superoxide formation, there is net flow of electrons from the 
CoQ pool to NAD+ while the redox state of the FMN is poised to support superoxide 
production (Figure 1B).  
For reperfusion injury the most important aspect of RET is that it produces far 
more superoxide than any other mitochondrial process (Murphy, 2009). Furthermore, 
superoxide production by complex I during RET only requires a high p and a reduced 
CoQ pool, both of which occur under physiological conditions (Figure 1C), in contrast to 
ROS production following non-physiological interventions, such as respiratory complex 
inhibition (Turrens et al., 1985). Therefore, RET stands out as a physiologically plausible 
mechanism for superoxide production in vivo. Consistent with RET at complex I driving 
IR injury, many inhibitors of complex I are protective against IR injury, including 
rotenone (Chen et al., 2006a; Lesnefsky et al., 2004), amobarbitol (Chen et al., 2006b), 
MitoSNO (Chouchani et al., 2013) and metformin (Cahova et al., 2015; Calvert et al., 
2008). The next question to consider is whether conditions that support RET – a high p 
from proton pumping by complexes III and IV and a reduced CoQ pool - arise upon 
reperfusion injury (Figure 1C).  
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A high protonmotive force during reperfusion may support RET 
Reperfusion will lead to p being rapidly restored as the reintroduction of oxygen drives 
proton pumping by complexes III and IV (Figure 1C). This observation is supported by 
evidence that isolated mitochondria and cells reestablish a high p within seconds of 
reperfusion (Chouchani et al., 2014; Kim et al., 2012; Korge et al., 2008). It is technically 
more challenging to assess changes in p in tissue slices, isolated perfused organs or in 
vivo, but the available data are consistent with a very rapid rise in p upon reperfusion 
(Venable et al., 2013). For isolated mitochondria a near-maximal p is required to drive 
RET (Chance and Hollunger, 1961), which is achieved by preventing ATP synthesis and 
by minimizing proton leak by sequestering free fatty acids (St-Pierre et al., 2002). This 
suggests that for RET to occur upon reperfusion of ischemic tissue, ATP synthesis and 
other mechanisms of p dissipation must be inhibited. ATP synthesis following 
prolonged ischemia is compromised by depletion of the intracellular adenine nucleotide 
pools (Grover et al., 2004; Harrison et al., 1998; Kinugasa et al., 2003). This occurs 
because as the ATP/ADP ratio progressively decreases during ischemia the accumulated 
AMP is deamidated and degraded to generate inosine and hypoxanthine, or further 
metabolized by the purine nucleotide cycle (Harrison et al., 1998; Kinugasa et al., 2003). 
Adenine nucleotide levels can take over 45 minutes to be restored to normoxic levels 
following reperfusion (Kinugasa et al., 2003; Lindsay et al., 1990), therefore p is likely 
to be high enough to sustain RET upon reperfusion. Consistent with this view, dissipation 
of p with uncouplers such as 2,4-dinitrophenol (DNP) and FCCP decrease IR injury and 
mitochondrial ROS production during early reperfusion (Hoerter et al., 2004; Korde et 
al., 2005).  
 
Accumulation of succinate during ischemia maintains a highly reduced CoQ pool 
that supports RET and p during reperfusion 
For RET from complex I to occur during IR the CoQ pool must be maintained highly 
reduced, so as to provide electrons to generate a near maximal p by complexes III and 
IV, while also donating electrons for reverse transport through complex I to the FMN site 
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(Figures 1B & 1C). To supply electrons continually to the CoQ pool during reperfusion, a 
store of reducing equivalents must be built up during ischemia. Supporting this 
possibility, IR injury requires a sufficiently long period of ischemia in order to produce 
mitochondrial ROS upon reperfusion: this varies with species and tissue but 20-25 
minutes of ischemia is required for significant IR injury in the mouse heart (Hasche et al., 
1995; Reimer et al., 1977; Wang et al., 2001). Ischemia could alter the abundance of 
many mitochondrial metabolites that can potentially act as electron stores during 
ischemia and CoQ reductants upon reperfusion (Chouchani et al., 2014; Hochachka and 
Mustafa, 1972; Hochachka et al., 1975). Recently our group set out to find metabolites 
that accumulated during ischemia in a range of tissues that underwent mitochondrial IR 
injury. Only three metabolites accumulated consistently in a wide range of tissues 
susceptible to IR injury (Chouchani et al., 2014). Two of these, hypoxanthine and 
xanthine, were well established to occur during ischemia and arose due to the breakdown 
of purine nucleotides by the purine nucleotide cycle (PNC) in response to ischemic AMP 
accumulation (Hagberg et al., 1987; Imai et al., 1964). The other metabolite, succinate, 
was a common ischemic signature across metabolically diverse tissues and it accumulated 
to a far greater extent than any other mitochondrial metabolite (Chouchani et al., 2014). 
Many previous studies had also shown that succinate increased during ischemia or anoxia 
(e.g. Hochachka and Mustafa, 1972; Hochachka et al., 1975), but this was seen as a 
general response to inhibition of the Krebs cycle. In contrast, these recent findings 
indicate that selective accumulation of succinate occurred due to reversal of succinate 
dehydrogenase (SDH), driven by accumulated ischemic NADH passing electrons through 
complex I on to the CoQ pool, which then reduces fumarate to drive selective succinate 
accumulation (Figure 2). There may also be a contribution to maintaining reduction of the 
CoQ pool by other pathways such as electron transfer flavoprotein (ETF) (St-Pierre et al., 
2002), -glycerophosphate dehydrogenase (Tretter et al., 2007), dihydroorotate 
dehydrogenase (Hey-Mogensen et al., 2014), and the hydrogen sulfide CoQ 
oxidoreductase (Libiad et al., 2014). 
The fumarate that accepts electrons from CoQH2 at SDH probably arises by a 
number of pathways that are activated during ischemia. One is the degradation of the 
AMP that accumulates during ischemia by the PNC to generate adenylosuccinate, which 
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is in turn broken down to fumarate by adenylosuccinate lyase (Figure 2). That this 
provides the fumarate that goes on to form succinate during ischemia is supported by the 
prevention of succinate accumulation with AICAR (Chouchani et al., 2014), a known 
inhibitor of adenylosuccinate lyase (Stone et al., 1993). As there is no specific fumarate 
transporter in the mitochondrial inner membrane, its movement to the mitochondrial 
matrix most likely occurs indirectly. Mitochondrial fumarate uptake probably follows its 
conversion to malate by cytosolic fumarate hydratase (Adam et al., 2013; Fiermonte et 
al., 1998), followed by exchange for succinate by the DIC (Fiermonte et al., 1998). In the 
matrix the malate is then converted back to fumarate by mitochondrial fumarate 
hydratase for subsequent reduction by SDH to succinate (Figure 2). There is also the 
possibility that transamination of aspartate to oxaloacetate contributes to ischemic 
succinate. The oxaloacetate will be reduced to malate, catalyzed by cytosolic malate 
dehydrogenase and driven by the ischemic accumulation of cytosolic NADH. This malate 
can then exchange for succinate via the DIC and generate fumarate as an SDH substrate 
as above. A role for aspartate transamination in succinate accumulation during ischemia 
is supported by the decrease of ischemic succinate by the transaminase inhibitor 
aminooxyacetate (Chouchani et al., 2014). Aspartate can in principle lead to fumarate via 
both the transamination and the PNC pathways (Figure 2) and consistent with this pre-
loading the heart with 13C aspartate prior to ischemia leads to increased 13C-incorporation 
into succinate (Chouchani et al., 2014). However, much more remains to be explored 
about how the supply of fumarate to SDH is brought about, but current evidence suggests 
that the metabolism of the NADH and AMP accumulated during ischemia will be central.  
The above model indicates that cytosolic malate exchanges for matrix succinate, thus 
succinate will accumulate in the cytosol. This process is facilitated because succinate is 
an excellent substrate for the mitochondrial DIC and is exchanged for malate as shown in 
Figure 2. Therefore the net flux during ischemia will be to convert fumarate to succinate, 
which will rapidly distribute throughout the cell (Chouchani et al., 2014). The several-
fold, selective accumulation of succinate suggests that this metabolite cannot be further 
processed during ischemia (Chouchani et al., 2014). Indeed, the conversion of succinate 
to succinyl-CoA is thermodynamically unfavorable under these conditions because 
succinyl-CoA synthetase reverse operation requires GTP and CoA, both of which are 
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depleted in ischemia (Figure 2). More broadly, these findings suggest that succinate 
accumulation is a key metabolic signature of ischemia. Consistent with a role in 
ischemic-signaling, succinate in the cytosol, probably in conjunction with elevated ROS 
(Guzy et al., 2008), can stabilize the hypoxia-inducible factors (HIFs) by inhibiting their 
HIF-α prolyl hydroxylases-mediated degradation, thus leading to activation of a 
pseudohypoxic response (Selak et al., 2005; Tannahill et al., 2013) (Figure 2). In 
addition, extracellular succinate can activate the G protein-coupled receptor GPR91, 
which may be a relevant sensor responding to the succinate released into the extracellular 
space by cell death or lysis following ischemia (He et al., 2004). In summary, it is clear 
that succinate can be accumulated in great amounts as a terminal electron sink during 
ischemia, thereby acting as a potential electron store that can be used to drive superoxide 
formation from complex I by RET during reperfusion. 
 
Oxidation of succinate during reperfusion 
The finding of succinate accumulation during ischemia was particularly intriguing in the 
context of ROS production during IR injury, as it has long been known that the most 
effective way of generating superoxide in isolated mitochondria is through RET driven 
by succinate oxidation (Boveris et al., 1972; Murphy, 2009; St-Pierre et al., 2002). In 
vitro succinate is rapidly taken up by mitochondria through the DIC and oxidized by 
SDH reducing the CoQ pool. This reduction of the CoQ pool drives proton pumping by 
complexes III and IV, leading to a large p, as long as there is limiting ADP and thus low 
p consumption for ATP synthesis. Under these conditions there is also extensive RET at 
complex I, that leads to superoxide and subsequent hydrogen peroxide formation in 
mitochondria. In vivo, the succinate that accumulates over time in ischemic tissues is very 
rapidly oxidized upon reperfusion back to baseline levels within 5 minutes (Ashrafian et 
al., 2012; Chouchani et al., 2014). This prompt clearance of succinate is likely due its 
rapid oxidation in the mitochondrial matrix, sustained by the uptake of cytosolic 
succinate via DIC in exchange for malate. This oxidation is required for RET driven ROS 
and IR injury, as was shown by manipulations that prevent the accumulation of succinate 
during ischemia (Chouchani et al., 2014). In this scenario accumulated succinate acts as 
 13 
an electron sink during ischemia, which is then used to drive ROS by RET at complex I 
upon reperfusion.  
 
The complex I active/deactive transition and reversible thiol modification in the 
prevention of IR injury  
As we propose that superoxide generation by RET at complex I upon reperfusion is the 
major source of IR injury, it is of particular relevance that complex I RET is dramatically 
altered by a structural change known as the active/deactive transition (Babot et al., 2014; 
Galkin et al., 2009). Our understanding of the active/deactive transition of complex I 
arose from the pioneering work of Vinogradov and colleagues (Babot et al., 2014; 
Kotlyar and Vinogradov, 1990; Vinogradov, 1998). When complex I is not oxidizing 
NADH and pumping protons across the mitochondrial inner membrane it gradually 
converts to a “deactive” state, which is characterized by a conformational transition 
(Kotlyar and Vinogradov, 1990; Vinogradov, 1998) (Figure 3A). The physiological role 
of the active/deactive transition is unclear, but in the context of IR injury the most 
interesting aspect is that complex I readily undergoes deactivation during ischemia with a 
half-life for deactivation of about 10-12 minutes (Ciano et al., 2013; Galkin et al., 2009; 
Gorenkova et al., 2013). Upon reperfusion complex I is rapidly reactivated and can 
support superoxide production by RET (Gorenkova et al., 2013) (Figure 3A).  
The active/deactive transition of complex I provides an appealing explanation for 
many therapeutic interventions that decrease IR injury. Deactive complex I exposes a 
critical cysteine residue (Cys39 in the ND3 subunit in mammals) that is occluded in 
active complex I (Chouchani et al., 2013; Galkin et al., 2008; Gorenkova et al., 2013; 
Zickermann et al., 2015) (Figure 3B). Importantly, covalent modification of Cys39 locks 
complex I in the deactive state preventing RET (Chouchani et al., 2013; Galkin et al., 
2008). Reversible modification of this cysteine residue by thiol reactive agents also 
temporarily locks complex I in the deactive state in vivo, thereby preventing ROS 
production by RET (Burwell et al., 2006; Chouchani et al., 2013; Galkin and Moncada, 
2007; Shiva et al., 2007). In this case the modification is reversed by endogenous thiol 
reduction mechanisms such as the mitochondrial glutathione and thioredoxin systems 
following the first minutes of reperfusion with a half-life of ~ 5 minutes (Chouchani et 
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al., 2013). The overall effect is that electron flow through complex I is temporarily 
prevented upon reperfusion, thereby blocking superoxide production by RET during the 
crucial first few minutes of reperfusion. As the modification is reversible, complex I 
returns to full activity a few minutes after reperfusion, by which time the succinate 
accumulated during ischemia will have been oxidized. Indeed, this modification was 
demonstrated using the mitochondria-targeted S-nitrosothiol MitoSNO, and underlies the 
protective action of S-nitrosating agents against IR injury (Burwell et al., 2006; 
Chouchani et al., 2013; Methner et al., 2014; Prime et al., 2009).  
More generally, similar reversible inhibition of complex I superoxide production 
by RET may explain a number of therapeutic interventions that decrease IR injury. 
Compounds can exert their effects by acting on Cys39 of the ND3 subunit of complex I 
when it is exposed during ischemia. These modifications include S-nitrosation by nitric 
oxide metabolites such as S-nitrosothiols (Kohr et al., 2011; Nadtochiy et al., 2007, 2009) 
and sodium nitrite (Chouchani et al., 2013; Shiva et al., 2007), S-sulfenylation by 
hydrogen sulfide (Elrod et al., 2007), oxidation to a sulfenic acid and/or to glutathione 
mixed disulfide in response to oxidative stressors such as hydrogen peroxide (Gorenkova 
et al., 2013; Yaguchi et al., 2003), ischemic preconditioning (Chouchani et al., 2013; 
Kohr et al., 2011) and post-conditioning (Tong et al., 2014) (Figure 3C). These 
modifications could then be reversed by reductants such as the mitochondrial glutathione 
and thioredoxin systems (Chouchani et al., 2013). These manipulations of complex I are 
likely to be clinically useful because they act through reversible post-translational 
modification of deactive complex I and have no impact on the active complex 
(Chouchani et al., 2013; Galkin et al., 2008; Galkin and Moncada, 2007).  
There are considerable uncertainties about the proportion of the complex I pool 
that undergoes the deactive transition in vivo. Furthermore, the way in which these 
changes in complex I activity link to their incorporation into supercomplexes and the 
extent to which this may alter the rates of interconversion and superoxide production are 
currently unclear. Even so, it is likely that a diverse range of therapeutic interventions act 
by inducing reversible modification of Cys39 on the ND3 subunit of complex I that is 
exposed following ischemia and thus prevents the burst of ROS due to RET upon 
reperfusion.  
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A unifying mechanism for mitochondrial superoxide production during IR injury 
The work discussed leads us to propose a unified model of IR injury. Defined metabolic 
transitions during ischemia re-route electrons to succinate, which acts as an electron store 
in the absence of oxygen (Figure 2). Upon reperfusion, succinate fuels RET due to the 
high p in the first minutes following ischemia, providing the initiating burst of 
superoxide that leads on to IR injury (Figure 1B & C). Many established therapeutic 
interventions act to decrease the accumulation of succinate during ischemia, its oxidation 
upon reperfusion or the generation of a large p upon reperfusion. Furthermore, many 
protective agents act by inhibiting RET by complex I, either by direct inhibition of the 
enzyme, or by temporarily locking complex I in the deactive state by reversible 
modification of Cys39. Many other potential therapies may act downstream of the burst 
of ROS, such as antioxidants that minimize the oxidative damage, compounds that block 
induction of the permeability transition pore and drugs that decrease the inflammatory 
response initiated by damaged mitochondria. This model helps rationalize the 
bewildering array of interventions that affect IR injury and provides a context for 
development of new therapies and to explore how other interventions such as ischemic 
preconditioning and cooling may exert their protective effects.  
 
Outlook 
The unifying mechanism for mitochondrial ROS production during IR injury that we 
propose raises intriguing issues. One pertinent question is why mitochondria are set up to 
produce large amounts of superoxide by RET at complex I. It seems probable that 
complex I RET has a physiological role, perhaps as a way for mitochondria to rapidly 
communicate their status by a retrograde redox signal to the rest of the cell. RET at 
complex I enables mitochondria to combine the effects of two processes that are central 
to their function: the electron supply to the respiratory chain, sensed via the reduction 
potential of the CoQ pool, and the ATP demand, which is indicated by the magnitude of 
p. Thereby mitochondrial RET would be accelerated when mitochondria are inactive 
and over-supplied with electrons and minimized when mitochondria are active. The 
superoxide would be converted to hydrogen peroxide that can diffuse to the cytosol 
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acting as a redox signal by modifying redox sensitive protein thiols. In IR injury this 
signaling pathway is over-stimulated, leading to oxidative damage.  
 The model we present provides a unifying framework for an array of data that 
provides a number of predictions that can be tested in future experiments while also 
suggesting approaches for the future development of targeted therapies against the 
generation of mitochondrial ROS in IR and related pathologies.  
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Figure legends 
 
Figure 1. Superoxide production by complex I during reperfusion injury 
(A) Operation of complex I in the forward direction oxidizing NADH in order to generate 
a protonmotive force (p) to be used to synthesize ATP. For forward electron transport to 
occur the difference in reduction potential between the NAD+/NADH and the Coenzyme 
Q (CoQ) pool across complex I (Eh) has to be sufficient to pump protons across the 
mitochondrial inner membrane against the p. As 4 protons are pumped for every 2 
electrons that pass through complex I, 2Eh > 4p is the requirement for the forward 
reaction to occur. The red arrow in complex I indicates forward electron transport. SDH, 
succinate dehydrogenase. 
(B) Reverse electron transport (RET) by complex I. When the p is large and/or the Eh 
across complex I is low such that 4p > 2Eh, electrons can be driven backwards from 
the CoQ pool onto the flavin mononucleotide (FMN) of complex I, reducing the FMN 
which can donate a pair of electrons to NAD+ to form NADH, or pass one electron to 
oxygen to generate superoxide. The red arrow in complex I indicates reverse electron 
transport. 
(C) The factors that favor RET at complex I during reperfusion. The condition to be met 
for RET to occur is that 4p > 2Eh. The rapid oxidation of the succinate that 
accumulates during ischemia favors reduction of the CoQ pool thereby maintaining a 
large Eh. The reduced CoQ pool also favors proton pumping by complexes III and IV 
helping maintain a large p upon reperfusion. In addition, the degradation of adenine 
nucleotides during ischemia limits ADP availability upon reperfusion that would 
otherwise diminish p by stimulating ATP synthesis.  
 
 
Figure 2. The pathways of succinate accumulation during ischemia and oxidation 
during ischemia-reperfusion injury 
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(A) Mechanisms of accumulation of succinate during ischemia. During ischemia 
succinate dehydrogenase (SDH) operates in reverse, reducing fumarate to succinate. This 
occurs due to the increased reduction of the CoQ pool, which arises in response to the 
build up of NADH during ischemia that transfers electrons to the CoQ pool via complex 
I.  Fumarate arises from the degradation of the AMP that accumulates during ischemia by 
the purine nucleotide cycle. This fumarate can then be hydrolyzed to malate by cytosolic 
fumarate hydratase. In parallel, deamination of aspartate to oxaloacetate transfer electrons 
from NADH in the cytosol to form malate. The malate in the cytosol is then exchanged 
for mitochondrial succinate by the action of the dicarboxylate carrier in the mitochondrial 
inner membrane. Once formed in the matrix, the succinate cannot go on to form succinyl 
CoA due to the lack of Coenzyme A (CoA) and GTP during ischemia. The succinate in 
the cytosol, probably in conjunction with elevated ROS (Guzy et al., 2008), can also 
activate the hypoxia inducible factor  pathway. AOA, aminooxyacetate; AICAR, 5-
aminoimidazole-4-carboxamide ribonucleotide; SDH, succinate dehydrogenase.  
  
 
Figure 3. The complex I active/deactive transition during IR injury  
(A) Schematic of complex I in the active and deactive states. During ischemia the 
complex adopts the deactive conformation that leads to cysteine 39 (red; bovine 
nomenclature) on the ND3 subunit (yellow) becoming exposed to the solvent. Upon 
reperfusion complex I is rapidly reactivated and then produces a burst of superoxide by 
RET. When exposed to the solvent Cys 39 can be reversibly modified (indicated as S-X) 
and can then be reactivated by mitochondrial matrix reductants such as the glutathione or 
thioredoxin systems. This slows the reactivation of complex I upon reperfusion 
consequently by the time complex I is fully active the succinate that drives RET has been 
oxidized and there is less superoxide production upon reperfusion.  
(B) The inset shows the structure of the homologous cysteine residue in the structure of 
deactive complex I from Yarrowia lipolytica (Zickermann et al., 2015) in the deactive 
state showing the cysteine equivalent to Cys 39 in mammals.  
(C) The Cys 39 of the ND3 subunit of complex I that is exposed in the deactive complex 
I can react with a number of agents that modify the cysteine and thereby hold complex I 
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in the deactive state. These modifications can be reversible (in red) such that complex I 
can be restored to full activity, or irreversible modifications that render complex I 
permanently inactive (in green).  
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